The drugmaker Gilead Sciences said on Monday that it would buy Kite Pharma for about $11.9 billion to bolster its aging portfolio with an emerging cancer treatment. With the deal, Gilead would acquire Kite's new cancer-fighting method, which harnesses the body's immune system to attack malignant cells.
Also, when did Gilead buy Kite Pharma?
On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share. The deal will add the promising CAR-T candidate to Gilead's existing portfolio. The acquisition was completed in October 2017.
Furthermore, who will Gilead acquire? Gilead Sciences (GILD) will buy cancer-focused player Forty Seven (FTSV) for $4.9 billion, the biotech company said Monday, sending FTSV stock rocketing. The deal was rumored last week and allows Gilead to harness Forty Seven's cancer drug, magrolimab.
In this way, did Gilead buy kite?
Gilead to buy Kite Pharma in $11.9 billion deal Gilead Sciences agreed to buy Kite Pharma in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions.
Who started Kite Pharma?
Arie Belldegrun Joshua Kazam
How many employees does Kite Pharma have?
2,000Where is Kite Pharma located?
About Kite Kite, a Gilead Company , is a biopharmaceutical company based in Santa Monica, California . Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies.When was Kite Pharma founded?
2009Who bought Juno Therapeutics?
CelgeneHow much cash does Gilead Sciences have?
Gilead has $32 billion in cash, but $27.4 billion is outside the U.S. and is unavailable for acquisitions unless Gilead pays U.S. tax on it, though it could borrow against it.Is Gilead stock a good buy?
Why the stock may be a good buy Gilead could be a calculated risk for investors to take today. At a forward price-to-earnings (P/E) ratio of just nine, and with the company still generating some good growth from its HIV drugs, there's reason to still be optimistic that the company can turn things around.Is Gilead a good investment?
Based on CAN SLIM investing principles, the short answer is no. Gilead stock is not a buy right now based on the metrics that other big winning stocks showed at the beginning of major price runs. Investors should look for stocks that beat expectations while growing sales and earnings.Why did Gilead stock drop?
Cherney. Gilead Sciences Inc. shares dropped about 2.5% in the extended session Thursday, after the drug maker beat Wall Street's earnings expectations but reported lower-than-expected sales. Analysts surveyed by FactSet had estimated adjusted earnings of $1.74 a share on revenue of $5.61 billion.Who owns Gilead?
Top 10 Owners of Gilead Sciences Inc| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 8.03% | 101,623,014 |
| Capital Research & Management Co. | 6.73% | 85,132,885 |
| BlackRock Fund Advisors | 5.58% | 70,527,295 |
| SSgA Funds Management, Inc. | 4.59% | 58,068,763 |
How do you pronounce Gilead?
He pronounces it Gil-EE-ad, and that's what I've gone with since. Audiobooks pronounce it "Gil-EE-add" so that's it for me.What stocks should I buy today?
20 of the Top Stocks to Buy in 2020 (Including the 2 Every Investor Should Own)- The Vanguard Total Stock Market ETF (NYSEMKT:VTI)
- The Vanguard Total International Stock ETF (NASDAQ:VXUS)
- Amazon.com (NASDAQ:AMZN)
- Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL)
- Facebook (NASDAQ:FB)
- Intuitive Surgical (NASDAQ:ISRG)
